The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

IDH1 Development

dmercer1
dmercer1 CSN Member Posts: 16
in Brain Cancer #1

Anyone else see this? Pretty exciting.

http://www.webwire.com/ViewPressRel.asp?aId=180575#.UkMGNbx5iqQ

Like Care

Comments

  • I_Promise
    I_Promise CSN Member Posts: 218 Member
    #2
    Thank you

    for sharing this info. I had not seen it. What is interesting is that the drug used 5-azacytidine is already an FDA approved drug for other cancers. So I guess an oncologist could always prescribe it off label if she/he wanted to... Of course you need to carry the mutation IDH1 mutation (present in 70-80% of low grade gliomas) to use this new drug. I hope they fast forward a clinical trial.

    J.

     

    Like Care

Discussion Boards